38 results about "Influenza antibody" patented technology

The present invention provides novel human anti-influenza antibodies and related compositions and methods. These antibodies are used in the diagnosis and treatment of influenza infection.

The present invention provides novel human anti-influenza antibodies and related compositions and methods. These antibodies are used in the diagnosis and treatment of influenza infection.

The present invention provides novel human anti-influenza antibodies and related compositions and methods. These antibodies are used in the diagnosis and treatment of influenza infection.

The present invention provides novel human anti-influenza antibodies and related compositions and methods. These antibodies are used in the diagnosis and treatment of influenza infection.

Methods for the quantification of influenza HA proteins and anti-influenza antibodies for the fields of vaccine-related protein quantification, potency determination, and efficacy evaluation are provided. According to the technology, quantification is achieved by providing capture agents attached to an array in a series of decreasing concentrations. Serial dilutions of a reference material also may be introduced. The reference material within each solution binds to the capture agents on the array and is labeled with a label agent capable of producing a detectable signal used to construct a calibration curve. A target material of unknown concentration is introduced to a separate identical array, and the target material binds to the capture agents and also is labeled by a label agent to produce a detectable signal. The calibration curve based on the reference material is then utilized to determine the concentration of the target material without the need to perform replicate experiments.

The present invention provides novel human anti-influenza antibodies and related compositions and methods. These antibodies are used in the diagnosis and treatment of influenza infection.

The present invention provides novel human anti-influenza antibodies and related compositions and methods. These antibodies are used in the diagnosis and treatment of influenza infection.

Vaccines that elicit broadly protective anti-influenza antibodies. The vaccines comprise nanoparticles that display HA trimers from Group 2 influenza virus on their surface. The nanoparticles are fusion proteins comprising a monomeric subunit (e.g., ferritin) joined to stabilized stem regions of Group 2 influenza virus HA proteins. The fusion proteins self-assemble to form the HA-displaying nanoparticles. Also provided are fusion proteins, and nucleic acid molecules encoding such proteins, and assays using nanoparticles of the invention to detect anti-influenza antibodies.

The present invention provides novel human anti-influenza antibodies and related compositions and methods. These antibodies are used in the diagnosis and treatment of influenza infection.

Vaccines that elicit broadly protective anti-influenza antibodies. Some vaccines comprise nanoparticles that display HA trimers from influenza virus on their surface. The nanoparticles are fusion proteins comprising a monomeric subunit (e.g., ferritin) joined to the stem region of an influenza HA protein. The fusion proteins self-assemble to form the HA-displaying nanoparticles. The vaccines comprise only the stem region of an influenza HA protein joined to a trimerization domain. Also provided are fusion proteins, and nucleic acid molecules encoding such proteins, and assays using nanoparticles of the invention to detect anti-influenza antibodies.

The invention discloses an influenza vaccine and a preparation method based on self-assembled ferritin nanometer antigen particles. In the present invention, the extracellular domain of the influenza virus hemagglutinin protein is fused and expressed with the N-terminal of the self-assembled ferritin nanoparticle subunit, and the influenza virus hemagglutinin protein is displayed on the surface of the self-assembled ferritin cage structure. The invention carries out mutation optimization of the influenza virus hemagglutinin protein, improves its soluble expression amount and expression efficiency, improves the immune efficacy and breadth of the vaccine, and improves the immunogenicity of the influenza virus hemagglutinin protein. The present invention utilizes E. coli prokaryotic expression system, silkworm and AcMNPV-insect cell eukaryotic expression system to express and prepare recombinant protein vaccine respectively, or generate antigen and induce antibody production by gene presentation of recombinant baculovirus in vertebrate in vivo tissue. The influenza vaccine of the invention can induce broadly neutralizing anti-influenza antibodies, can not only improve the immune efficacy but also expand the immune range, and has the potential of a universal vaccine with cross-immunity efficacy.

The invention belongs to the field of biotechnology, and relates to a monoclonal antibody for recognizing the HA stem of influenza virus, an antigenic epitope, a coding gene and applications thereof. The present invention provides an influenza virus HA stalk-specific monoclonal antibody, including a heavy chain variable region and a light chain variable region, and the nucleotide and amino acid sequences of the heavy chain variable region are respectively shown in SEQ ID NO.1‑2 shown; the nucleotide and amino acid sequences of the light chain variable region are shown in SEQ ID NO.6-7 respectively. The monoclonal antibody specifically recognizes the epitope of the stem of the HA protein with the 431st W, 433rd Y, and 437th L as core motifs. The monoclonal antibody is obtained by immunizing mice with H7N9 subtype avian influenza virus HA protein as an antigen. It has high affinity and strong sensitivity, and has good cross-reactivity with group 1 and group 2 influenza viruses. It has high application value in scientific detection.

The present disclosure relates to a polypeptide comprising hemagglutinin stem domain fragments that can elicit broadly cross-reactive anti-influenza antibodies and confer protection against influenza virus. The disclosure also provides a method of preparing the polypeptide with biochemical and biophysical properties that enhance its immunogenic properties. Also provided are recombinant DNA constructs, vectors, and host cells comprising the nucleic acid encoding the polypeptide, as well as uses of the polypeptide, particularly in the prevention, and detection of influenza.

The invention relates to a multi-respiratory tract antigen detection card, which includes influenza A virus antigen test strips, influenza B virus antigen test strips, respiratory adenovirus antigen test strips, respiratory syncytial virus antigen test strips and Mycoplasma pneumoniae antigen test strips, Influenza A virus antigen test strips, Influenza B virus antigen test strips, Respiratory adenovirus antigen test strips, Respiratory syncytial virus antigen test strips and Mycoplasma pneumoniae antigen test strips all include Colloidal gold conjugate pads, colloidal gold conjugate pads include streptavidin conjugate pads and double-nanoparticle double-labeled antibody conjugate pads; the test strips in this test card can fully react biological raw materials and improve the sensitivity of antigen detection , effectively reducing missed detection, and adding blocking agents to the sample pad to improve specificity, and can simultaneously detect influenza A virus, influenza B virus, respiratory adenovirus, respiratory syncytial virus, and Mycoplasma pneumoniae antigens.